Why does Haystack MRD matter to you and your health system?  Ultrasensitive minimal residual disease (MRD) testing delivers novel insights that can help inform treatment decision-making, personalizing the guidance for patients and empowering healthcare providers to improve patient lives with high certainty. It can also have a positive effect on the bottom line.¹ Knowing the presence of disease can help guide treatment decisions and may result in cost savings to patients and your health system.

What is Haystack MRD? Purpose-built, high-precision minimal residual disease testing

Gain insights like never before with Haystack MRD—a tumor-informed, next-generation test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover minimal residual disease with exceptional clarity.

Packed with the power of Quest

At Quest, we know that having the right diagnostic information can turn into proactive action or prevent unnecessary treatment to improve patient outcomes.

That’s why we are a single source offering the latest innovation that’s not only better for patients but also your health system’s bottom line​. From early detection screening to diagnosis, monitoring, and beyond, our tests provide critical insights that make a meaningful difference for patients every step of the way.